About This Research Desk

What Kiss Peptide is

Kiss Peptide is an independent editorial reference desk covering the published research on two peptides studied in the context of sexual and reproductive biology: kisspeptin and PT-141 (bremelanotide). The site exists to make a specialized and often overstated literature legible — to tell a reader, in plain language and with citations, what each compound was actually studied for, in which populations, and how far that evidence reaches.

The organizing frame is the reproductive hormone axis and the neuroscience of sexual desire — two systems that are related but distinct. Kisspeptin acts upstream on the endocrine axis that produces sex hormones. PT-141 acts centrally on the brain circuits that generate the experience of desire. Reading them together gives a more complete picture of how the reproductive and sexual systems can be studied from different entry points. Each compound has its own page, a comparison page lines them up side by side, and a single shared references list aggregates every source across the site.

How it is compiled

Three principles govern what appears on this site.

First, everything is anchored to the peer-reviewed literature. Every research claim is tied to a numbered citation — PubMed-indexed journals, FDA regulatory documents, and systematic reviews — collected on the references page. Where a finding comes from a review rather than a primary study, the review is cited as such.

Second, the evidence is reported at its true strength. Doses and outcomes are described in the population and context in which they were studied — for example, "3.2 nmol/kg subcutaneously in IVF patients at high OHSS risk" — never translated to human recommendations. Where an approval is narrow (PT-141's single indication), that narrowness is stated prominently and not softened. Where evidence is Phase 1 and Phase 2 only (kisspeptin), that stage is the headline, not the footnote.

Third, cautions are part of the record. Tachyphylaxis in kisspeptin, nausea and blood-pressure effects in PT-141, the limits of what research-grade material actually is — these are not caveats appended at the end. They are facts from the same literature that documents the benefits, and this desk gives them the same weight.

What it is not

Kiss Peptide is not a store, not a clinic, and not a source of medical advice. It does not sell, supply, source, or broker any peptide or research chemical, and it has no affiliate or referral relationship with any vendor. It does not employ clinicians, diagnose conditions, or prescribe anything. It does not recommend a dose, schedule, or route of administration for any person.

The peptides discussed here have specific regulatory statuses that matter: kisspeptin is investigational and has no approved form anywhere; PT-141 (bremelanotide) is FDA-approved only for premenopausal women with HSDD, and material sold as "PT-141 research chemical" is not the approved pharmaceutical. The research summaries on this site do not change those facts, and they are not a basis for self-administration. Readers interested in any condition described in the underlying research should consult a licensed clinician operating within their own jurisdiction.